[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363579-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363579-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","treatment-patterns-and-clinical-outcomes-of-metastatic-gastric-cancer-in-south-korea-real-world-evidence-from-retrospective-electronic-medical-records-data","Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea - real-world evidence from retrospective electronic medical records data","","Treatment patterns and outcomes for metastatic gastric cancer in South Korea remain insufficiently characterized, despite known regional differences between Eastern and Western populations. This retrospective analysis evaluates electronic medical records, assessing therapy sequencing across 2,229 patients and clinical outcomes across 2,083 patients. Results quantify biomarker positivity and first-to-third line treatment use, and report overall survival patterns, including benefits with immune checkpoint inhibitor–based strategies across HER2 statuses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/treatment-patterns-and-clinical-outcomes-of-metastatic-gastric-cancer-in-south-korea-real-world-evidence-from-retrospective-electronic-medical-records-data/363579/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/treatment-patterns-and-clinical-outcomes-of-metastatic-gastric-cancer-in-south-korea-real-world-evidence-from-retrospective-electronic-medical-records-data/363579.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on metastatic gastric cancer in South Korea?","Question",{"text":63,"@type":64},"To evaluate treatment patterns and clinical outcomes for patients with metastatic gastric cancer in South Korea using retrospective electronic medical records.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were treatment patterns and clinical outcomes assessed?",{"text":68,"@type":64},"Treatment patterns were evaluated in 2,229 patients, and clinical outcomes were assessed in 2,083 patients from retrospective electronic medical records data.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about survival across treatment lines and regimens?",{"text":72,"@type":64},"A survival benefit was observed with multiple lines of therapy, particularly involving immune checkpoint inhibitor (ICI) therapy, with improved overall survival in both HER2-positive and HER2-negative patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363579,1791497361,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Kim etal. BMC Cancer (2026) 26:713 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15811-y](https://doi.org/10.1186/s12885-026-15811-y)  \nRESEARCH Open Access  \nTreatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data  \nEunah Kim1, Ju-Young Shin1, Sejung Park2, Ju Hee Yoo2, Woo Sun Kwon2, Choong-kun Lee2,3, Minkyu Jung2,3, Hyo Song Kim2,3, Hyun Cheol Chung2,3 and Sun Young Rha2,3*  \nAbstract  \nBackground Five-year survival of patients with metastatic gastric cancer (mGC) is poor. Tumor characteristics, timing of diagnosis, and treatment patterns differ between patients from Eastern and Western regions. Therefore, we aimed to evaluate treatment patterns and outcomes of patients with mGC in South Korea.  \nMethods This retrospective study aimed to analyze electronic medical records. Treatment patterns were evaluated in 2,229 patients, and clinical outcomes were assessed in 2,083 patients.  \nResults The median age of the included patients was 60 (range, 18–92) years (62 . 8%, male; 95. 5% had Eastern Cooperative Oncology Group performance status score of 0–1) . Among tested patients, HER2-positivity, microsatellite instability high/deficient mismatch repair (MSI-H/dMMR), and PD-L1 22C3 Combine Positive Score ≥ 1 rates  \nwere 16. 0%, 4 . 7%, and 49 . 1%, respectively. Of the 2,353 patients, 94 . 7%, 68 . 0%, and 52. 9% received first-line (1 L), second-line (2 L), third-line (3 L) therapy, respectively. Platinum doublets were used for 1 L (61 . 3%); paclitaxel plus ramucirumab, 2 L (50 . 6%); and, irinotecan-based therapy, 3 L (51 . 1%) . The median overall survival (OS) was 3.8 and 16.3 months in the untreated and treated patients, respectively. Overall, HER2-positive patients treated with HER-2 targeted agent had a longer OS (19 .1 months), and those treated with combined HER2-targeted plus immune checkpoint inhibitor (ICI) therapy (23 .1 months) had the longest OS. In HER2-negative patients, OS was 15.7 months with chemotherapy, and 17.6 months with combined chemotherapy plus ICI. No survival differences were found between patients treated with oxaliplatin and cisplatin in 1 L, irinotecan and taxane in 2 L/3L, and across 2 L to 3 L sequences.  \nConclusions A survival benefit was observed with multiple lines of therapy, particularly with immune checkpoint inhibitor (ICI) therapy, in both HER2-positive and HER2-negative patients. Our findings support the benefits of multiline personalized treatments in mGC.  \nKeywords Gastric Cancer, Metastatic, Electronic Medical Records, HER2-targeted, Immune Checkpoint Inhibitors  \n*Correspondence: Sun Young Rha [RHA7655@yuhs.ac](RHA7655@yuhs.ac)  \n1School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangangu, Suwon, Gyeonggi-do, Republic of Korea  \n2Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea  \n3Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need t","cbCaiemforxr61ZR","https://ap.wps.com/l/cbCaiemforxr61ZR","pdf",1546395,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main goal of the study on metastatic gastric cancer in South Korea?\",\"answer\":\"To evaluate treatment patterns and clinical outcomes for patients with metastatic gastric cancer in South Korea using retrospective electronic medical records.\"},{\"question\":\"How were treatment patterns and clinical outcomes assessed?\",\"answer\":\"Treatment patterns were evaluated in 2,229 patients, and clinical outcomes were assessed in 2,083 patients from retrospective electronic medical records data.\"},{\"question\":\"What did the study find about survival across treatment lines and regimens?\",\"answer\":\"A survival benefit was observed with multiple lines of therapy, particularly involving immune checkpoint inhibitor (ICI) therapy, with improved overall survival in both HER2-positive and HER2-negative patients.\"}]","Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea - real-world evidence from retrospective electronic medical records data | PDF",1790151920,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/796ebcd11f840317e1170218e7432428.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68e5d771416f206771a7d5fe508934c3.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6f95ecb061b9d43b0540b10ad19cbac.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d27836d4d2aee30b8b9039cdc484f9a.webp",980,1306]